Protection's coverage gap: the FCA's quiet test of Consumer Duty

The FCA has closed its Pure Protection Market Study without new market-wide measures, choosing instead to press firms on obligations they already carry. The final report concludes the market functions well for those already insured, while roughly 58% of adults hold no protection cover at all (Polar Insight Regulatory Tracker). That restraint is itself the intervention: the regulator is signalling that the Consumer Duty and product governance rules are sufficient, provided boards use them.

Key Executive Takeaways

• The FCA has declined to impose new rules on pure protection but expects firms to use Consumer Duty and product governance to address a coverage gap affecting most UK adults (Polar Insight Regulatory Tracker).
• Enforcement risk now sits with firms that treat the existing rulebook as a ceiling rather than a mandate to expand access and improve outcomes (Polar Insight Regulatory Tracker).
• A TechSprint on medical records access is open for expressions of interest until 13 November 2026, giving insurers and intermediaries a route to shape underwriting infrastructure (Polar Insight Regulatory Tracker).

A market study that hands the pen back to boards

The headline finding matters less than the regulatory posture behind it. By declining to prescribe remedies while stating publicly it will act against firms falling short of existing requirements (Polar Insight Regulatory Tracker), the FCA has framed the coverage gap as a governance failure waiting to be tested. Chief executives and product committees should read MS24/1.5 as a supervisory brief, not a policy document. The absence of new rules removes the excuse of waiting for clarity.

The planned webinar to address perceived rule misunderstandings that firms cite as barriers to innovation (Polar Insight Regulatory Tracker) is a pointed move. It suggests the FCA believes firms are hiding behind interpretive caution to justify inaction on product design, distribution reach, or underwriting friction. Once that ambiguity is publicly resolved, the defence that a rule was unclear becomes considerably harder to sustain in a Section 166 review or enforcement referral.

Where stakeholder pressure will concentrate

Boards should expect three vectors of scrutiny. First, product governance committees will need documented evidence that target market definitions genuinely reach underserved segments, not just the profitable existing base. Second, distribution economics, particularly commission structures and adviser incentives, will attract renewed attention if they correlate with the coverage gap. Third, fair value assessments will need to reconcile strong outcomes for current customers with the reality that most adults are outside the market entirely.

Investors in listed insurers should note the asymmetry. A market described as working well for existing customers is a market where growth requires reaching the uninsured majority, and the regulator has now made that expansion a Consumer Duty obligation rather than a commercial choice. Firms that treat protection as a mature, stable book risk being outpaced by those that read the study as a mandate to redesign for access.

The TechSprint signal

The invitation to participate in a TechSprint aimed at reducing delays in obtaining medical records, with expressions of interest due by 13 November 2026 (Polar Insight Regulatory Tracker), is worth taking seriously. Underwriting friction is a recognised suppressant of take-up, and firms shaping the infrastructure early will influence the standards others must meet.

The FCA has chosen persuasion over prescription. Senior leaders who mistake that for lenience will find the enforcement path shorter, not longer.